Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife’s balance sheet stewards more than half a trillion dollars in insurance reserves and invested assets—numbers that translate into multi-layered disclosures spanning hundreds of pages. Finding where management explains reserve adequacy or how separate-account assets back variable annuity guarantees can feel daunting.
Stock Titan solves that problem. Our AI engine converts each MetLife annual report 10-K into an easy synopsis, highlights key shifts in credit‐quality of the investment portfolio, and flags loss-ratio trends inside every MetLife quarterly earnings report 10-Q filing. Need rapid context on a dividend declaration or reinsurance treaty? The moment a MetLife 8-K material events filing arrives in EDGAR, we post it with an “8-K material events explained” note. Real-time alerts also cover
- MetLife Form 4 insider transactions real-time
- MetLife proxy statement executive compensation
- MetLife executive stock transactions Form 4
Whether you’re comparing segment profit drivers or monitoring statutory capital, our platform keeps every document at your fingertips: MetLife insider trading Form 4 transactions, MetLife annual report 10-K simplified, MetLife SEC filings explained simply, and MetLife earnings report filing analysis. Stop combing through actuarial footnotes; understanding MetLife SEC documents with AI means you save hours and surface insights faster than ever.
MetLife has filed a Form 144 notice for the proposed sale of 1,024 shares of common stock with an aggregate market value of $81,879.04. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 27, 2025.
The securities to be sold were acquired in three separate purchases during 2013:
- 31 shares from Deutsche Bank on January 31, 2013
- 902 shares from Goldman Sachs on March 13, 2013
- 91 shares from Goldman Sachs on May 15, 2013
Recent trading activity shows that related entities have sold 1,256 shares in the past three months, totaling approximately $99,076.70 in gross proceeds. The filing was made by the MetLife 401(k) Plan Trust, which maintains an affiliate discretionary manager relationship with the issuer. The company has 671,297,826 shares outstanding.
MetLife has filed a Form 144/A notice for the proposed sale of securities, detailing planned transactions of 547 shares of common stock with an aggregate market value of $42,966.85 through Barclays Capital on the NYSE, scheduled for June 20, 2025.
The securities to be sold were originally acquired in two separate purchases from Deutsche Bank:
- 272 shares acquired on September 20, 2013
- 275 shares acquired on March 21, 2014
Recent trading activity in the past 3 months includes sales by various MetLife accounts totaling 686 shares with combined gross proceeds of $55,391.75. The largest transaction was by the MetLife 401k Plan Trust-Large Cap Equity Index, selling 335 shares for $27,590.60 on March 21, 2025. The company has approximately 671.3 million shares outstanding.
MetLife has disclosed preliminary variable investment income estimates for Q2 2025 in an 8-K filing. The company projects variable investment income to be between $175 million - $225 million (pre-tax) for the quarter ended June 30, 2025. This includes income from private equity, real estate and other funds, and prepayment fees.
Key points from the disclosure:
- Full Q2 2025 earnings release and financial supplement scheduled for August 6, 2025
- Preliminary figures are unaudited and subject to change pending completion of financial closing procedures
- Management emphasizes these results are estimates based on currently available information
The filing was signed by Toby S. Brown, Executive Vice President, Global Head of Reinsurance and Interim Chief Accounting Officer. The company includes standard cautionary language regarding forward-looking statements and notes this disclosure is being furnished under Regulation FD requirements.
MetLife, Inc. (MET) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a planned sale of 27 shares of its common stock. The shares, carrying an aggregate market value of $2,120.85, are slated for sale on or about 20 June 2025 through Barclays Capital, 745 Seventh Ave, New York, NY 10019. The notice cites 671,297,826 shares outstanding, making the proposed transaction an immaterial fraction of total equity.
The filer also reported prior dispositions over the past three months totaling 686 shares for gross proceeds of roughly $55,392, executed on 21 March 2025 and 13 June 2025 by various MetLife-related accounts. The signing party affirms that no undisclosed material adverse information exists and that Rule 10b5-1 representations are satisfied.
MetLife, Inc. (MET) filed a Form 144 with the SEC disclosing a proposed sale of 360 common shares through Barclays Capital on or after 20 June 2025. The shares have an aggregate market value of $28,278, compared with the company’s 671,297,826 shares outstanding, representing less than 0.0001 % of total equity—an immaterial amount from an ownership-dilution perspective.
The filer originally acquired the shares on 29 May 2015 via a purchase from Goldman Sachs for cash. The notice affirms the seller’s representation that no undisclosed material adverse information is known.
Recent trading history: in the last three months, related MetLife accounts collectively sold 686 shares for $55,391.75 in gross proceeds. These transactions, combined with the planned 360-share disposition, remain de minimis relative to MetLife’s market capitalization and average daily trading volume. No financial performance data, strategic updates or governance changes accompany the filing.
Given the modest size and routine nature of the transaction, the filing is unlikely to influence MetLife’s valuation or trading dynamics.
MetLife, Inc. (MET) – Form 144 filing: The notice discloses a proposed sale of 101 common shares with an aggregate market value of $7,933.55. The shares were originally purchased on 12/17/2019 for cash and are slated to be sold through Barclays Capital on or about 06/20/2025 on the NYSE. The issuer has 671,297,826 shares outstanding, so the planned transaction represents less than 0.00002 % of equity. The filing also lists earlier sales by related MetLife accounts over the past three months totaling 686 shares for gross proceeds of $55,391.75. The signer affirms no undisclosed material adverse information and Rule 144 compliance.
MetLife Director Robert Glenn Hubbard acquired 964 shares of common stock on June 17, 2025, at a price of $77.85 per share, bringing his total direct beneficial ownership to 100,489 shares.
The acquisition was part of MetLife's non-management director compensation arrangements, where a portion of director retainer fees is paid in company common stock. Hubbard elected to defer the receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Key transaction details:
- Transaction type: Acquisition of non-derivative securities
- Total value of transaction: Approximately $75,047 (964 shares × $77.85)
- Ownership form: Direct
- Filing made as an individual reporting person
MetLife Director Jeh C. Johnson reported the acquisition of 562 shares of common stock at $77.85 per share on June 17, 2025, bringing total direct ownership to 6,789 shares.
The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Johnson elected to defer the receipt of these shares through the MetLife Deferred Compensation Plan for Non-Management Directors.
- Transaction Type: Acquisition (Code A)
- Form Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Transaction Value: Approximately $43,752
- Ownership: Direct
This routine compensation-related transaction demonstrates continued alignment between director and shareholder interests through equity-based compensation.
MetLife director Denise M. Morrison reported the acquisition of 562 shares of common stock on June 17, 2025 as part of the company's non-management director compensation arrangements. The shares were acquired at $0 cost as part of director retainer fees paid in company stock.
Following this transaction, Morrison now beneficially owns a total of 32,817 shares directly. The filing indicates this is a routine compensation-related acquisition for board service rather than an open market purchase.
- Transaction Type: Stock Award (Compensation)
- Form of Ownership: Direct
- Role: Non-Management Director
- No derivative securities were involved in this transaction
MetLife director Christian Stephane Mumenthaler acquired 562 shares of common stock on June 17, 2025 at a price of $77.85 per share, bringing total direct ownership to 918 shares.
The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Notably, Mumenthaler elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
- Transaction Type: Acquisition (Form 4)
- Total Transaction Value: $43,751.70
- Ownership Type: Direct
- Role: Non-Management Director
FAQ
What is the current stock price of MetLife (MET)?
What is the market cap of MetLife (MET)?
What are the core business segments of MetLife?
How does MetLife generate revenue?
What is MetLife's significance in the insurance industry?
How does MetLife manage risk across its global operations?
How does the U.S. segment contribute to MetLife's operations?
What differentiates MetLife from its competitors?
What types of insurance products does MetLife offer?
How does MetLife incorporate industry-specific practices in its operations?
